The Challenges of Harmonizing Biomarker Data
Why Trial Success Depends on It
Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
For full access to this article login to GEN Select now.
Protein Production Continues to Post Gains
Latest Advances Demonstrate that Biological Limits Have Yet to Be Achieved
- There are a variety of ways in which the problem of low protein yields in bioprocessing platforms can be addressed. These include vector design, cell-line selection, and media optimization. In addition, the properties of the product must be taken into account, including folding and secondary modifications, especially glycosylation. Oxford ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.